Zika as still another argument for a new path to vaccine development

Clinical Microbiology and Infection

Volumn 22, Issue 4, 2016, Pages 294-295

  Plotkin, S A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

UNCLASSIFIED DRUG; VIRUS VACCINE; ZIKA VIRUS VACCINE;

EPIDEMIC; FINANCIAL MANAGEMENT; HUMAN; LEGAL LIABILITY; MOSQUITO; NEGLECTED DISEASE; NONHUMAN; NOTE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; RESEARCH ETHICS; STUDY DESIGN; VIRUS; WESTERN HEMISPHERE; ZIKA VIRUS; DRUG APPROVAL; DRUG DEVELOPMENT; ECONOMICS; FEMALE; HEALTH CARE POLICY; ISOLATION AND PURIFICATION; NEWBORN; PREGNANCY; ZIKA VIRUS INFECTION;

DRUG APPROVAL; DRUG DISCOVERY; FEMALE; HEALTH POLICY; HUMANS; INFANT, NEWBORN; PREGNANCY; VIRAL VACCINES; ZIKA VIRUS INFECTION;

EID: 84963780532     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2016.03.001     Document Type: Note

References (3)

1. Pronker E.S., Weenen T.C., Commandeur H.R., Osterhaus A.D., Claassen H.J. The gold industry standard for risk and cost of drug and vaccine development revisited. Vaccine 2011, 29:5846-5849.
2. Pronker E.S., Weenen T.C., Commandeur H., Claassen E.H., Osterhaus A.D. Risk in vaccine research and development quantified. PLoS One 2013, 8(3):e57755.
3. Plotkin S.A., Mahmoud A.A., Farrar J. Establishing a Global Vaccine-Development Fund. N Engl J Med 2015, 373:297-300.